

Policy Document

Futuristic Biotechnology (FBT) is an official Journal of "Lahore Medical Research Center LLP" (LMRC) and is being funded by Lahore Medical Research Center (LMRC). Pakistan Journal of FBT is a quarterly, open access, double blind peer-reviewed international journal that publishes in all fields of Health sciences for an internationally diverse authorship. Futuristic Biotechnology (FBT) publishes broad-spectrum publications with close connection to experimental activity in Biological and Biotechnology fields. FBT is intended for exploring the molecular mechanisms that support key biological processes in the fields of biochemistry, cellular biosciences, molecular biology, plant biotechnology, genetic engineering, nanotechnology, and bioinformatics. Furthermore, it also covers topics related to immunology, antibody production, protein purification studies, primer synthesis, DNA sequencing, production of transgenic animal models, insect resistant crop varieties and edible and ornamental plant varieties.

A. Guideline for submission of articles

1. Article Policies

Publication of any material in FBT denotes that all its authors have agreed to its content and have ensured that FBT's policies have been fully adhered to. Non-compliance with these policies may mean that an article fails the pre-publication checks and cannot be published. Authors of posters and slides must ensure that their research and presentations adhere to the policies outlined for posters and slides.

2. Originality

All articles submitted to FBT must be original; the work, or large parts of it, must not have been published previously or be currently under consideration or review elsewhere. If there is any significant overlap with another paper, this must be cited in the article and mentioned on submission.

Khurram Mehboob
Director ORIC
Lahore Medical Research Center LLP




Prof. Dr. Riffat Mehboob Ph.D.
Editor-in-Chief
Futuristic Biotechnology
Lahore Medical Research Centre LLP



Articles previously posted on a preprint server, such as ArXiv, bioRxiv, agriRxiv or PeerJ Preprints can be submitted for publication in FBT. Posters and slides already posted on FBT can be written up as articles, following our article guidelines, and submitted to FBT. Submitted articles with content that infringes copyright may be rejected if the problematic sections cannot be removed. Authors who wish to reproduce a figure or table from a previous copyrighted publication are responsible for obtaining the permission of copyright holders and for clearly referencing the original source. Figures that were previously published under a creative commons license may be reused under the condition of the [specific license](#) that applies to those figures.

B. Peer Review Policy

This Policy is applicable to all publications submitted to the research journals of the Lahore Medical Research Center and operates a double-blind peer review process. The Editorial Board of the Journal is responsible for the selection of reviewers based on their expertise in the relevant field. The manuscript is sent to two external reviewers (from outside the organization of journal) for a peer review. The entire publication process completes in a range of 40-45 days. In case of conflict of interest regarding a specific manuscript, a member of the Editorial Board will be assigned to assume responsibility for overseeing peer review. Reviewers will be treated anonymously and the pre-publication history of each article will not be made available online. Intentionally falsifying information, for example, authors or reviewers with a false name or email address, will result in rejection of the manuscript and may lead to penalty according to misconduct policy. Guest editorial submitted by authors is reviewed internally by Editor-in-Chief or Editor and is then sent externally to another guest editor for final verdict.



C. Plagiarism Policy

Plagiarism is the presenting of another author's language, text, thoughts, ideas, or expressions as one's own unique work. Self-plagiarism is also included, which includes duplicate/redundant publication, content recycling, and salami slicing. FBT adheres to the COPE, ICMJE, and HEC (Higher Education Commission) of Pakistan recommendations, norms, and policies on plagiarism. FBT uses TURNITIN to check the similarity index, and notifications are sent to the authors if it is greater than 50%. If it is greater than 50%, it will be rejected without further inspection or processing. For authenticity, the Higher Education Commission (HEC) of Pakistan

needs a similarity of less than 20%. If the authors have already checked the paper with the same software, they can submit the similarity report as a supplementary file. Plagiarism is considered academic dishonesty. If it is proven after the article has been published, it will be retracted, the authors may be permanently or temporarily blocked, and the parent institution may be notified for departmental proceedings against the author. If it is proven before publication, the present work will be rejected, and the authors may be prohibited from submitting to this journal for one or more years.

1. Adoption of HEC Policies

As mentioned earlier, all anti-plagiarism policies, rules, regulations and guidelines provided by HEC shall be adopted and fully implemented university-wide in letter and spirit. HEC also issues notifications from time to time as an on-going activity. Therefore, all such notifications shall be deliberated at appropriate forum(s) of FBT for adoption/adaptation in the light of Journal structure/settings.

2. Turnitin

Turnitin is an internet-based plagiarism detection service, being used globally to check plagiarism. It helps students, faculty, and researchers etc. to determine a similarity index of the submitted documents. HEC is incessantly advising to use Turnitin for checking plagiarism in assignments, papers and reports etc. FBT has already been making use of this extremely useful plagiarism detection software. It shall continue to use this software in official capacity. The Journal shall offer Turnitin services as per following guidelines:

4.1 Who is Eligible to Get a Turnitin Account?

The Lahore Medical Research Center and our Journal officials shall be eligible for Turnitin account by the virtue of their positions. The supervisors/ LMRC members may also obtain Turnitin account on recommendations of management.

4.2 Code of Conduct

The students/Researchers are expected to:

- Ensure the observance of the universal moral principles of research
- Abide by all FBT & LMRC research policies, rules, regulations and guidelines etc.
- Follow local and international applicable research policies and established practices
- Avoid immoral research practices
- Apply suitable and relevant research methods
- Conclude on the basis of critical analysis of the evidence
- Report completely and correctly, the findings of a research
- Keep clear, complete and accurate records of all research
- Acknowledge the individuals who made contributions to the research
- Obtain informed consent from the respondents/unit of analysis, for example, surveys in case of Social Sciences, a declaration to the respondents/unit of analysis on the assurance of confidentiality and right to withdraw from study at any time prior to data collection
- Keep privacy/secrecy when reviewing others' work
- Avoid plagiarism of all nature

Note: Refer to HEC guidelines on 'Ethics of Using Turnitin for Administrators and Faculty'. Standard Operating Procedure (SOP) while carrying out research work, the main supervisor can check plagiarism of thesis using officially provided Turnitin account or can request the focal person/HOD of the concerned department under his/her own discretion. The supervisor shall maintain record of complete plagiarism reports of interim documents, for ready reference, as and when required. The final plagiarism report for placement in the hard bound copies shall be generated through officially provided Turnitin account and duly signed by the student, supervisor and the Convener DRC.

4.3 Duty to Report

All FBT & LMRC community members have the implicit duty to report to the authorities concerned, in good faith and without fear, any suspected research misconduct like fabrication, falsification and plagiarism etc. and/ or any incident where known facts indicate a possibility of a code or policy violation.

4.4 Policy Audit

QEC shall arrange the audit of departments, libraries etc. to check the implementation of the aforementioned policies and SOPs.

4.5 Policy Revision

The policy shall be revised, as and when required.

D. Ethical Considerations

If tables, illustrations or photographs, which have already been published, are included, a letter of permission for re-publication should be obtained from author (s) as well as the editor of the journal where it was previously published. Written permission to reproduce photographs of patients, whose identity is not disguised, should be sent with the manuscript; otherwise, the eyes will be blackened out. If a medicine is used, generic name should be used. The commercial name may, however, be mentioned only within brackets, only if necessary. In case of medicine or device or any material indicated in text, a declaration by author/s should be submitted that no monetary benefit has been taken from manufacturer/importer of that product by any author. In case of experimental interventions, permission from ethical committee of the hospital should be taken beforehand. Any other conflict of interest must be disclosed. All interventional studies submitted for publication should carry Institutional Ethical & Research Committee approval letter. Ethical consideration regarding the intervention, added cost of test, and particularly the management of control in case-control comparisons of trials should be addressed: multi-centric authors' affiliation may be asked to be authenticated by provision of permission letters from ethical boards or the heads of involved institutes.

1. Authorship Criteria

As stated in the Uniform Requirements, credit for authorship requires substantial contributions to (a) the conception and design or analysis and interpretation of the data, (b) the drafting of the article or critical revision for important intellectual content, (c) critical appraisal of findings with

literature search and actual write up of manuscript, (d) final approval of the version to be published. Each author must sign a statement attesting that he or she fulfills the authorship criteria of the Uniform Requirements. The Journal discourages submission of more than one article dealing with related aspects of the same study. The journal also discourages the submission of already published case reports. Unusual but already reported cases should, therefore, be submitted as letters to the editor.

2. Copyright

Instructions to authors appear on the last page of each issue. Prospective authors should consult these before submitting their articles and other material for publication. The FBT accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in this journal. The Editorial Board makes every effort to ensure the accuracy and authenticity of material printed in the journal. However, conclusions and statements expressed are views of the authors and do not necessarily reflect the opinions of the Editorial Board or the FBT. Publishing of advertising material does not imply an endorsement by the FBT.

3. Proofs

Page proofs will be emailed, without the original manuscript, to the corresponding author for proof correction and should be returned to the editor within three days. Major alterations from the text cannot be accepted. Any alterations should be marked, preferable in red.

E. Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.

F. Author Agreement Form

Sr. No	Author's Name	Department and Institute	Contributions to the Paper (Please Give Brief Description of the Role of Each Author Separately)	Signatures
1.				
2.				
3.				
4.				

FUTURISTIC BIOTECHNOLOGY

LETTER OF AUTHORSHIP

Dear Editor:

This is to confirm that the manuscript titled _____

_____ submitted for publication in Futuristic Biotechnology (FBT), has been read and approved by all authors. I/We, the author(s), confirm that:

- ◆ The submitted manuscript is a new article. Subject matter of this paper has not been published, wholly or in part, nor has it been and neither will be submitted for publication elsewhere while it is under consideration of FBT.
- ◆ Once this document is submitted, no change in authorship will be accepted.
- ◆ All the authors have made a substantial, direct, intellectual contribution to the conception, design, analysis and/or interpretation of the data.
- ◆ We take full responsibility of the content reported in the manuscript.
- ◆ If any question arises about the accuracy or validity of the research work during the review process, the author(s) should provide raw data to the Editor.
- ◆ We transfer the copyrights of this manuscript to Futuristic Biotechnology (FBT).

The Submitted article is ☐ Original Research Article ☐ Review Article ☐ Case Report ☐ Commentary ☐ Systematic Review ☐ Other (Specify): _____

5.				
6.				
7.				
8.				
9.				
10.				

Name of Corresponding Author: _____

Email ID: _____

Contact Number: _____

Conflict of Interest Statement

☐ The authors declare no conflict of interest

☐ If any, please narrate: _____

Source of Funding

☐ The author(s) received no financial support for the research, authorship and/or publication of this article

☐ Please specify, if any: _____

Disclaimer: Futuristic Biotechnology (FBT) acknowledges original work that holds scientific novelty however, it also reserves the right to remove and retract a plagiarized article upon identification of subtle (simply copy-paste) and/or blatant (paraphrasing) type of plagiarism at any stage before or after acceptance and/or publication.

Signature & Stamp

G. Review of articles

Submitted manuscripts are reviewed for originality, significance, adequacy of documentation, reader interest and composition. Manuscript not submitted according to instructions will be returned to the author for correction prior to beginning the peer review/process. Revised manuscripts are judged on the adequacy of responses to suggestions and criticisms made during the initial review. Each manuscript will be checked for technical, epidemiological, statistical, and ethical and language corrections. All parts of accepted manuscripts are subject to editing for scientific accuracy and clarity by the office of the Editor. The editorial board of FBT holds the right to a final decision of accepting or rejecting any article from publication in the journal, at all stages including the editorial review.

H. Instructions to the Authors and Reviewers of the Manuscripts

INTRODUCTION

The Editorial Board of FBT decided to follow the “Uniform requirements for manuscripts submitted to Biomedical Journals: writing & Editing for Biomedical Publications by International Committee of Medical Journal Editors. A brief account of minimum requirements is given below for assisting the authors, reviewers and editors, the full text can be read at, (www.icmje.org). Moreover, plagiarism policy of ICMJE, Higher Education Commission and PMDC will be observed. It is authors’ responsibility to apprise them of plagiarism in any form including paraphrasing and self-plagiarism. The Plagiarism Standing Committee of FBT would deal with cases of plagiarism and comprise of staff members, and editors. Those claiming intellectual/ idea or data theft of an article must provide documentary proof in their claim otherwise their case will be sent for disciplinary action.

APPEALS PROCESS

The readers, authors, reviewers or any other person may submit a formal appeal through official email (editor@fbtjournal.com) of the journal regarding any problem, including but not limited to any conflict, delays in review or publishing or article processing charges or rejection of manuscripts to the Chief Editor. The case will be referred for examination/ investigation to the Appeals Committee of the Editorial Board/ Advisory Board to give recommendations to the Board for decision. The Committee is comprised of;

1. Dr. Muhammad Akram Tariq
2. Dr. Humera Kausar
3. Dr. Farhat Bano

COMPLAINTS PROCESS

Regarding any publication misconduct on the part of an author, a reviewer, or the Editor/Editorial Board, readers, writers, or any other person may send a written complaint to the Chief Editor using the journal's official email address (editor@fbtjournal.com). The Complaints Process Committee

of the Editorial Board/Advisory Board will be asked to investigate the issue and make suggestions to the Board regarding its course of action. The Committee is comprised of;

1. Dr. Muhammad Ayaz Anwar
2. Dr. Sumaira Anjum
3. Dr. Aditya Mojumdar

GENERAL PRINCIPLES

Submission of Manuscripts

Only original material in the manuscript will be considered for publication. Neither the manuscript nor essential substance of the manuscript should be submitted for publication elsewhere before appearing in this journal.

Online submission

On our website, the corresponding author must create an account or login to an existing account. Then he must complete a 5-step simple submission process. The manuscript must be blinded, with no indication of the authors' names, designations, departments, institutions, or towns. Author information should be included in metadata. If required, supplemental files such as data files, fee submission documents, and so on can be included.

Language

FBT is published in English. Use of British English is preferred however American English can also be employed where convenient.

Writing Style and format

Please use Times New Roman, size 12, justified, with a line spacing of 1.0. Tables and illustrations (figure/ chart/ image) should be placed where specified, not at the conclusion of the document.

Submission Format According to the type of Manuscript

Review article: Maximum 3500 words excluding references.

Original article: Maximum 2500 words excluding structured abstract of 250 words and 20 references (minimum).

Short Reports / Short Communications / Special Communications / Case reports: Maximum 1250 words excluding title page and an unstructured abstract of 150 words with no more than two tables or figures and 10 references. It should not be signed by more than six authors.

Title of the manuscript

It must include the study's design, objectives, and variables. It should also include information about the characteristics and geographical location of the population of interest. Use of abbreviations should be avoided in title. Each manuscript should include five to ten key words. These should be included in the Medical Subject Headings (MeSH) of the United States National Library of Medicine, which may be found at: <https://meshb.nlm.nih.gov/>

Abbreviations

Only standard abbreviations should be used. For each abbreviation, the full term should be presented first, followed by the abbreviation in parenthesis. A well-known and widely used abbreviation may be used in this capacity.

Tables and Illustrations

1. There is no limit to the number of tables and illustrations (graphs/ charts/ images) that can be included. These should be in accordance with the manuscript's rational demand.
2. Each table and illustration should stand alone, displaying all of its contents/meanings without referring to the text.
3. Each table and illustration must have a legend below the table/illustration. The title of the table and picture should be a summary of the manuscript's title.
4. Illustrations must be of high quality. Graphs and charts should be editable.
5. Where applicable, a legend should be included with the table or illustration.
6. If a table or illustration is taken from a published work, the source must be cited.
7. To reproduce a previously published illustration, the author must obtain permission from the author/publisher.

References

1. Vancouver style must be followed.
2. References should be numbered serially and given in digits within the text, as in standard medical journals.
3. Add authors. Give last/family/surname in full, then first letter of 1st and 2nd names as capital with no gap. Add six authors. In case of more than six authors, et al should be added after six authors.
4. Journal titles should be abbreviated as in Index Medicus/Medline/PubMed/NLM Catalogue. If not in Index Medicus, then it should be abbreviated as by the journal itself.
5. Add DOI where available; otherwise add online link.
Here is an example for a journal article: Ishaq T, Khattak MI, Amin S, Haq NU. Frequency and risk factors for hepatitis C among pregnant women. Gomal J Med Sci 2011; 9:166-9.

Units of Measurements

Please use Systems International (SI) units, where possible.

Drug Names

Generic names of drugs are preferred. Where essential the brand names can be given in parenthesis.

ORIGINAL ARTICLE

Abstract: Word count should be within 250. It may be up to 350 in exceptional cases. It should have the following sub-headings: Background, Material & Methods, Results, and Conclusion. Background includes 1-3 sentences regarding the introduction of your problem/s of interest and objective/s. Material & Methods include study design, duration, setting, population & sampling, and data collection (variables and their attributes and types) and analysis plans (descriptive, estimation of parameters and hypotheses testing). Conclusion is the summary of your results in simple words.

Text

The main part of the original research article should follow IMRAD; to have the following sub-headings: Introduction, Material and Methods, Results, AND Discussion & Conclusion.

A. INTRODUCTION: This section should have nearly all the following components.

Bring here data in quantities (numbers & figures) regarding all your variables of interest as per your objectives. It may include prevalence and/or incidence of the disease of interest/ under investigation, its distribution by socio-demographic factors, its various determinants or its treatment. Instead of prevalence, distribution, determinant and treatment of a disease, the researcher may determine any health related event in a population, like level/ concentration/ score of some anthropometric measure/ biochemical parameter, like weight, height, blood pressure (BP), random blood sugar (RBS) etc. Here bring the level/ concentration/ score of your parameters of interest. The data is collected from global populations/ studies, then regional, then national and lastly local populations/ studies. The manuscript should clearly state research problem, knowledge gap, research question, research objective, hypothesis and significance of the study.

B. MATERIALS AND METHODS

This section should have nearly all the following components.

1. Design, setting & duration

Please mention the study design (cross-sectional/case-control/cohort/ trial) with name of the academic/ professional department and name of the academic/ professional institution with city and country. It shows ownership. Add duration of the study with day, month and year.

2. Technical approval from the institutional research board and ethical approval from institutional ethical committee & patients' consent.

3. Population & sampling

Research is a problem solving activity for a specified population; never for a sample. Please specify/ define your population by count, geographic location, socio-demographic and disease factors. Then tell how you calculated the sample size as required by the design of your study with formula/calculation or online calculator/software with reference/link. Then give sampling technique. Then give inclusion and exclusion criteria for one group or separately for each group in case of two or more groups.

4. Equipment, procedure, intervention and follow up

Please narrate here all the steps which you took from enrolment of a subject to its discharge from the study, including history, general & systemic examination, investigations and any intervention (health education, food, exercise, vaccine, drug, device, laser or surgery). Please give details of different equipment, instruments, appliances and tools used, giving the name, model, version, company name and its manufacturing city name in parenthesis.

5. Data collection plan

1. Data collection methods (physical procedures to collect data)
 - a. Literature survey (secondary data; the data of other researchers collected, mostly qualitative)
 - b. Questionnaire
 - c. Interview
 - d. Observation: clinical examination, laboratory & imaging tests, pre, per and post drug-treatment/ device-procedure/ operation notes/ findings as morbidities, disabilities, mortalities. (b, c and d give us primary & first hand data, the data which we generate ourselves from the sample, mostly quantitative). Tell which one or more methods of data collection are used by you.
2. Questionnaire is framed from literature. The data on research variables is collected by questionnaire. Qualities are transformed into quantities (qualitative variable/data to quantitative variable/data) as in Knowledge, Attitude & Practice (KAP) Surveys. It gives us quantitative data. Its reliability is pretested by a pilot study by selecting sample from a sample and is shown as Cronbach's alpha. It should be based on a 5-point Likert scale, with a range of 1-5 scores (strongly disagree, disagree, neutral, agree & strongly agree, respectively) respectively for each response. It includes respondent demographic. The questionnaire must not be on nominal or ordinal scale.
3. Questionnaire; To-do list
 - a. Items (questions) are extracted from literature (existing knowledge)
 - b. Designed as per list of variables, their attributes & their relationship as per theoretical framework
 - c. Items should be short & to the point
4. Avoid in framing a questionnaire; Not-to-do list
 - a. Double-Barrel items/questions (Qs)
 - b. Putting words in mouth of respondent (leading Qs)
 - c. Memory dependent Qs; should base on cash memory
 - d. Emotional loaded Qs (positive emotion=happiness, negative are anger, fear, sadness & hatredness)
 - e. Personal Qs (private, vary from culture to culture)
 - f. Technical Jargons

- g. Too many
- h. Too long
- i. Negative Qs. I do not like computer. If negative are used, then reverse the scoring at analysis.

5. Name the demographic variables: gender, age in years, age groups, education level, residence, experience, income etc.

6. Name the research variables: pain in flank, category of pain in throat, level of knowledge, level of attitude, level of practice, weight in Kg, height in cm, volume in ml, RBS in mg/dL, T3 level in pcg/ml

7. In case of categorical (nominal or ordinal) variable, tell the attributes (categories/ groups) of the variable

- a. Age grouping was; group 1 up to 50 years, group 2 more than 50 years in a study “prevalence of HTN in employees of a bank”
- b. Age in years was categorized as; group 1= 40-49, group 2 = 50-59, group 3 = 60-69, group 4 = 70 and above years for a study “prevalence of DM in adult age shopkeepers”
- c. The two attributes of residence were urban and rural
- d. The five attributes of education level were: matric = group 1, graduation = group 2, masters = group 3, MPhil = group 4 and PhD = group 5
- e. Level of knowledge, level of attitude and level of practice (KAP) were determined by a questionnaire based on 5-point Likert Scale. There were so many questions for each of the three KAP variables with a range of 1-5 scores (strongly disagree, disagree, neutral, agree & strongly agree, respectively) for each question.

8. Identify independent, dependent, confounding and matching variables, where required

9. Tell the data types (nominal/ordinal/interval/ratio); gender, residence and pain in flank were nominal data. Age groups, education level, and category of pain in throat were ordinal data. Age in years, level of knowledge, level of attitude, level of practice (all three on Likert Scale), pain score (on visual analogue pain scale-VAPS), weight in Kg, height in cm, volume in ml, RBS in mg/dL, T3 level in pcg/ml were interval/ ratio/ numeric/ continuous data.

10. Attach Performa and questionnaire. if any.

11. Mention which calculator or software was used for data analysis

6. Data analysis plan

Research is for a specified population; never for a sample. It is ideal to observe the entire population, but it is not feasible. Statistics as a discipline helps us in collecting data for a sample, analyze it for the sample (descriptive statistics; describe the sample) and then infer it on to the population from which it was drawn (inferential statistics; describe the population based on the data collected from the sample). Inferential statistics includes estimation of parameter and hypothesis testing.

Global literature is full of research articles which are restricted to sample, with no mention of the population. For us, it may be anything, but not research.

Our authors have to give analysis plan for all the three components of the statistical analysis. It is widely stated and widely accepted narrative that the cross-sectional studies don't require hypothesis. It is a miss-understanding. Cross-sectional studies do require hypothesis. There may be some one dozen cross-sectional studies, each with many hypotheses published in this journal from 2018 to 2021, regarding burden/ magnitude (prevalence/ distribution) of malaria, leishmaniasis, DS-TB, DR-TB etc.

Data analysis is simply a process of converting data (un-organized facts & figures) into information (organized facts & figures). Both qualitative and quantitative data are organized as per requirements of the topic and end users of the findings. When analyzed (organized),

qualitative and quantitative facts and figures are mixed together to form a single piece of information or knowledge.

There are two types of analysis.

Qualitative analysis

Qualitative data includes text, picture, audio and video. This analysis is based on qualitative argumentation (not included here).

Quantitative analysis

Quantitative data includes nominal, ordinal, interval and ratio data. This analysis is based on statistical computations (included here).

Descriptive analysis

It is the analysis of data collected from the sample. Here each variable is described separately without talking about its difference between the groups or within the groups or its relationships to any other variable in the same population.

Categorical (nominal and ordinal data) is analyzed by count and percentage. Numeric (interval and ratio) is subjected to tests of normality; Skewness, kurtosis, Kolmogoro-Smirnov test & histogram. If it is distributed normally; then it is analyzed by mean, minimum, maximum, range and SD. If it is distributed not normally (skewed); then it is analyzed by median (quartile 2), quartile 1 (Q1), quartile 3 (Q3) and Inter Quartile Range ($IQR=Q3-Q1$).

Inferential analysis: Here the data for the sample is inferred on to population. It includes estimation of parameters and testing of hypotheses.

Estimation of parameters

Here an interval is constructed around a sample statistic to estimate a parameter i.e. mean or proportion for a population at certain level of confidence, usually 95%. It is represented as confidence interval of mean or proportion, both with lower and upper bounds.

The mean RBS of the sample ($n=350$) was 110 (95% CL, 105.5-114.5) mg/dL. The frequency (%age) of diabetes mellitus in the sample ($n=300$) was 45 (15%, 95% CL, 12.5-17.5).

C. RESULTS

1. Preparing the sample for analysis; number of subjects

1. Total number of participants/ respondents/ subjects/ cases/ patients/ controls/ animals/ specimens/ plants/ microorganisms enrolled/ included at inception/ start of the survey/ study/ trail

2. Group wise number of participants/ subjects/ cases/ patients/ controls at inception

3. Frequency (count) & percentage of responses of the respondents in case of questionnaire based survey

4. Mention if any subject died?

5. How many were dropped out & why? Mention different causes with numbers of subject separately i.e. due to which complications of the drugs/ devices/ laser/ surgical procedure etc.

6. How many were lost to follow up?
7. Mention the missing data at follow ups
8. The rest of the subjects are the actual size of the sample/s to be analyzed
2. Descriptive analysis: Please analyze and write here your findings as explained in data analysis plan.
3. Estimation of parameters: Please analyze and write here your findings as explained in data analysis plan.
4. Testing of hypotheses: Please analyze and write here your findings as explained in data analysis plan.

D. DISCUSSION

1. Put your findings for your first objective/ variable. Then add studies with similar findings from local, then national, then regional and lastly global studies/ literature/ populations. Then add studies with higher findings (higher prevalence/proportion/mean) and lastly with lower findings. Likewise go for your next objectives/ variables one by one.
2. The comparison is to be based on estimation of parameters (indices of population) and not on sample statistics (sample indices). Further it should be based on hypotheses testing, but most studies lack both the estimation of parameters and hypotheses testing.
3. The comparisons must be based on numbers/ indices (counts, percentages and means) from populations, not merely on theoretical/logical/philosophical statements/argumentation.
4. Each study brought for comparison should have author name, city & country name, duration of study, sample size and relevant data for comparison.
5. Better to bring those studies which are already cited in introduction.
6. Other studies may have data for many more objectives/ variables. You have to bring only relevant data matching to your objective/ variables.
7. Conclusion is the last part of the discussion. It is actually summary of your results. What you observed and analyzed in your study, bring those facts here in non-statistical language as statement in simple English. Do not bring conclusions from work of other authors.
8. Recommendations may be added as separate heading or it may be the last paragraph of the conclusion. Here you may go beyond your own findings.

E. CONCLUSION

It should be based on the objective and principal findings. False ambiguous conclusion and speculations should be avoided.

F. References

1. Vancouver style must be followed.
2. References should be numbered serially and given in digits within the text, as in standard medical journals.
3. Add authors. Give last/family/surname in full, then first letter of 1st and 2nd names as capital with no gap. Add six authors. In case of more than six authors, et al should be added after six authors.

4. Journal titles should be abbreviated as in Index Medicus/Medline/PubMed/NLM Catalogue. If not in Index Medicus, then it should be abbreviated as by the journal itself.
5. Add DOI where available; otherwise add online link. Here is an example for a journal article:
Sharmin SN. Prognostic Value of Serum D-dimer in Predicting Outcomes in COVID-19 Positive Pregnant Women. Scholars International Journal of Obstetrics and Gynecology. 2024; 7(11): 554-9. doi: 10.36348/sijog.2024.v07i11.004.

Guidelines for Authors and Reviewers


All material submitted for publication should be sent exclusively to FBT. Work that has already been reported in a published paper or is described in a paper sent or accepted elsewhere for publication, should not be submitted. Multiple or duplicate submission of the same work to other journal should be avoided as this fall into the category of publication fraud and are liable for disciplinary consequences, including reporting to Pakistan Medical & Dental Council and Higher Education Commission. A complete report following publication of a preliminary report, usually in the form of an abstract, or a paper that has been presented at a scientific meeting, if not published in full in a proceedings or similar publication, may be submitted. Press reports of meetings will not be considered as breach of this rule, but additional data or copies of tables and illustrations should not amplify such reports. In case of doubt, a copy of the published material should be included with a manuscript for editors' consideration.

Authors can submit their articles by E-mail: editor@fbtjournal.com to the Editor, FBT. All authors and co-authors must provide their contact telephone/cell numbers and E-mail addresses only on the title page of manuscript. A duly filled-in letter of authorship is mandatory for publication. The sequence/order of the authors on letter of authorship once submitted shall not be changed at any stage. It is mandatory to provide the institutional ethical review board / committee approval for all research articles, at the time of submission of article. The editors reserve the right to edit the accepted article to conform to the house-style of the Journal.

J. Timelines of publication of issues

The duration from submission to first decision is around 40-45 days. FBT is a quarterly journal. Our first issue period is from January-March, second issue period is from April- June, third issue period is from July-September and forth issue period is October-December every year.

K. Steps involved from date of receipt of research article till the publication of article



L. Article processing/publication fee

The processing charges of FBT are as follows:

Fee & Subscription Charges

Article Processing Fee: NONE

Article Publication Fee (National): Rs 20000 / Article

Article Publication Fee (International): 200 USD / Article

Annual Subscription for Printed Versions

For Institutes: Rs 20,000/Annually

Single Copy: Rs 2500/-

Waiver Policy

If an author has no funds to pay such charges, he may request for full or partial waiver of publication fees. The decision may however vary from case to case. We do not want charges to prevent the publication of worthy material.

M. Disclosure and Conflicts of Interest

Authors must include a 'Competing interests' statement. A competing interest will not preclude publication, but it provides full transparency for the reviewers and readers. If there are no competing interests to declare, the following standard statement is added: 'No competing interests were disclosed'.

A competing interest may be of non-financial or financial nature. Examples of competing interests include (but are not limited to):

- Individuals receiving funding, salary or other forms of payment from an organization, or holding stocks or shares from a company, that might benefit (or lose) financially from the publication of the findings;
- Individuals or their funding organization or employer holding (or applying for) related patents;
- official affiliations and memberships with interest groups relating to the content of the publication;
- Political, religious, or ideological competing interests.

Authors from pharmaceutical companies, or other commercial organizations that sponsor clinical trials, should declare these as competing interests on submission. The relationship of each author to such an organization should be explained in the ‘Competing interests’ section. Publications in FBT must not contain content advertising any commercial products. The International Society for Medical Publication Professionals provides good practice guidelines, which are aimed at ensuring that “clinical trials sponsored by pharmaceutical companies are published in a responsible and ethical manner”. Reviewers are also required to declare any competing interests in their reports, as are readers who contribute comments on the site. If an undisclosed competing interest is brought to the attention of the editorial office after publication, FBT will follow the COPE guidelines.

N. Conflict of interests

This Policy states that FBT requires authors to declare conflict of interests in relation to their work. All submitted manuscripts must include a ‘conflict of interests’ section at the end of the manuscript and also in letter of authorship listing all competing interests (financial and non-financial) duly signed by all authors. Where authors have no competing interests, the statement should read “The author(s) declare(s) no conflict of interest”. The Editor may ask for further information or documents relating to conflict of interests. Editors and reviewers are also required to declare any competing interests and may be excluded from the peer review process if a competing interest exists. Competing interests may be financial or non-financial. A competing interest exists when the authors’ interpretation of data or presentation of information may be influenced by their personal or financial relationship with other people or organizations. Authors should disclose any financial competing interests but also any non-financial competing interests that may cause them embarrassment if they were to become public after the publication of the manuscript. FBT requires disclosure of financial conflict of interests that include (but are not limited to: Receiving reimbursements, fees, funding, or salary from an organization that may in any way gain or lose financially from the publication of the manuscript, either now or in the future. Holding stocks or shares in an organization that may in any way gain or lose financially from the publication of the manuscript, either now or in the future. Holding, or currently applying for, patents relating to the content of the manuscript. Receiving reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript. Authors from pharmaceutical companies, or other commercial organizations that sponsor clinical trials, should declare these as conflict of interests on submission and publications should be produced in a responsible and ethical manner. The policies also apply to any company

or individuals that work on industry-sponsored publications, such as freelance writers, contract research organizations and communications companies. FBT also requires disclosure of non-financial conflict of interests that include (but are not limited to) political, personal, religious, ideological, academic, and intellectual competing interests. Public trust in the scientific process and the credibility of published articles depend in part on how transparently conflicts of interest are handled during the planning, implementation, writing, and publication of scientific work.

O. Correction and Retraction of Research Articles

Correction to an Article

In traditional journals, where articles are peer reviewed before publication, Corrections (or Errata) are published to alert readers to errors in the article that became apparent following the publication of the final article. By contrast, articles in FBT undergo peer review post publication and publication is not ‘final’ as new versions can be added at any stage. Possible mistakes that come to light during the peer review process may be highlighted in the published peer review reports, which are part of the article. Authors can publish revised versions, and any errors that become apparent during peer review or later can be corrected through the publication of new versions. Corrections and changes relative to the previous version are always summarized in the ‘Amendments’ section at the start of a new version.

Retraction

Articles may be retracted for several reasons, including:

- Honest errors reported by the authors (for example, errors due to the mixing up of samples or use of a scientific tool or equipment that is found subsequently to be faulty)
- Research misconduct (data fabrication)
- Duplicate or overlapping publication
- Fraudulent use of data
- Clear plagiarism
- Unethical research

For any retracted article, the reason for retraction and who is instigating the retraction will be clearly stated in the Retraction notice. The retraction notice will be linked to the retracted article (which usually remains on the site) and the article will be clearly marked as retracted (including the PDF). An article is usually only retracted at the authors’ request or by the publisher in response to an institutional investigation. It is important to note in the context of FBT’s publication model, that - as in traditional journals - a retracted article is not ‘unpublished’ or ‘withdrawn’ in order for it to be published elsewhere. The reasons for retraction are usually so serious that the whole study, or large parts of it, are not appropriate for inclusion in the scientific literature anywhere. The content of a retracted article would only be removed where legal limitations have been placed upon the publisher, copyright holder or author(s), for example, if the article is clearly defamatory or infringes others’ legal rights, or if the article is the subject of a court order. In such cases, the bibliographic information for the article will be retained on the site along with information regarding the circumstances that led to the removal of the content.

Under rare circumstances, for example, if false or inaccurate data have been published that, if acted upon, pose a serious health risk, the original incorrect version(s) may be removed and a corrected version published. The reason for this partial removal would be clearly stated on the latest version.

Disclaimer: Futuristic Biotechnology (FBT) acknowledges original work that holds scientific novelty however, it also reserves the right to remove and retract a plagiarized article upon identification of subtle (simply copy-paste) and/or blatant (paraphrasing) type of plagiarism at any stage before or after acceptance and/or publication.

P. Contribution and Consents of Each Author

Publication criteria and authorship

The FBT platform is set up to make it easy for active scientists, clinical researchers and research scholars in all fields to share their research rapidly, and to facilitate a constructive academic discussion. Articles on FBT must represent scholarly work that is suitable for formal peer review, so only authors with sufficient training as researchers in subject areas covered by FBT are able to publish. An objective requirement for publication of an article presenting research is therefore primarily based on authorship, as outlined below. (Please note that some gateways have more specific criteria (e.g., a requirement for authors to be affiliated with a specific organization); details can be found in each gateway under “About this gateway”).

Publication criteria for research outputs presenting original data and results:

- Authors must have a formal appointment at a recognized research or clinical institution (or organization) and have reached a certain level of research-based qualification (such as a PhD or MD). An author's activities as an active researcher or scholar should usually be obvious from his/her recent publication record.
- For disciplines outside the sciences, where doctorates are not necessary, a Masters qualification or equivalent may be sufficient; however, the author must have an appointment at a recognized institution and be able to demonstrate his/her activities within the research community (e.g., previous scholarly publications).
- At least one author on the article (who should have made a key contribution to the article) must meet these key criteria for it to be suitable for publication in FBT.
- Scientists, clinical researchers and scholars who wish to submit their research, but who do not meet our standard authorship criteria, will need to be endorsed by an experienced researcher, who does meet our authorship criteria. The author(s) should send the name and details of their nominated endorser to the editorial office. Any nominated endorser will be asked to confirm the expertise of the author(s), as well as the scientific standard of the submission. A statement to explain this, along with the endorser's name and affiliation will also be included in the published paper.

Publication of Reviews and Opinion articles

FBT encourages open, scholarly review and debate of research findings, trends and topics that are of direct relevance to researchers in the form of Reviews and Opinion articles. Submissions of this type must represent a useful addition to the scientific literature and must be presented in a format that is suitable for peer review. While researchers who meet the criteria outlined above are entitled to publish any article presenting new research and data, the decision of whether a submitted review or opinion article is suitable for publication and subsequent open peer review by experts, ultimately lies with FBT's Editorial Director.

All authors should have made a clear contribution to the published article. As a guide, authors should refer to the criteria for authorship that have been developed by The International Committee of Medical Journal Editors (ICMJE). Each author's contribution must be detailed by selecting Credit roles on the article submission form.

Anyone who has contributed but does not meet the criteria for authorship (for example, purely technical or writing assistance) should be listed in the 'Acknowledgments' section. The involvement of any professional scientific or medical writer assistance must be declared. Authors should obtain permission to include the name and affiliation, from all those mentioned in the Acknowledgments section.

Changes in authorship: If the author list of an article changes following its publication, a new version of the article can be published with an explanation included in the 'Amendments' section at the top of the new version. Any changes in authorship must be confirmed by all authors. If the editorial team is unable to contact an author, the corresponding author is responsible for facilitating communication. In agreement with COPE guidelines, the editorial team cannot take responsibility for resolving any disputes over authorship; any disagreements amongst the authors must be settled by the authors' institution(s).

Changes to author names: FBT understands that authors, reviewers or commenters may wish to change their names for many reasons, including marriage, divorce, gender identity recognition and other personal reasons. Following a name change request, the editorial office will require confirmation of the identification of the individual, and in the event of a name change on an author list will notify the corresponding author. Any change of name will not require a new version to be created, all existing versions will be edited to reflect the change; the DOI will remain the same. A Notice of Change will be posted to make readers aware that a name change took place with the following standard text: 'A name change in the author list of this article was requested. The change was implemented on'. Please note that FBT considers it a violation of publishing and personal ethics to request to change the name of another individual without their explicit consent. If an author, reviewer or commenter requires a name change, please contact the editorial office.

Khurram Mehboob
Director ORIC
Lahore Medical Research Center LLP

Prof. Dr. Riffat Mehboob Ph.D.
Editor-in-Chief
Futuristic Biotechnology
Lahore Medical Research Centre^{LLP}